



## MSD PO disclosure Methodology Statement 2022

According to the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) code of conduct, published 15/12/2022, each KEFEA member must disclose a list of POs to which it provides support (whether financial or non-financial) or with whom it has engaged to provide contracted services for that KEFEA member.

This disclosure includes a description of the nature of the support or services provided that is sufficiently complete to enable the average reader to form an understanding of the nature of the support or the arrangement without the necessity to divulge confidential information.

In addition to the name of the PO, the following elements are included:

- a. For support:
  - i. the monetary value of financial support and of invoiced costs.
  - ii. the non-monetary benefit that the PO receives when the non-financial support cannot be assigned to a meaningful monetary value.
- b. For contracted services: the total amount paid per PO over the Reporting Period.

Date of publication: MSD publishes the PO disclosure report for the preceding calendar year no later than 6 months after the end of the relevant reporting period.

Disclosure platform: MSD provides its annual PO disclosure report via the [MSD website](#).

Disclosure language: MSD provides its annual disclosure in English.

Currency: All disclosed ToV's are reported in local currency.

VAT: Disclosed ToV's to POs reflect the amounts agreed in the contracts between MSD and the PO and are exclusive of VAT.